Slow CD4+ T-Cell recovery in human immunodeficiency virus/hepatitis B virus-coinfected patients initiating truvada-based combination antiretroviral therapy in Botswana

Motswedi Anderson, Simani Gaseitsiwe, Sikhulile Moyo, Kerapetse P. Thami, Terence Mohammed, Ditiro Setlhare, Theresa K. Sebunya, Eleanor A. Powell, Joseph Makhema, Jason T. Blackard, Richard Marlink, Max Essex, Rosemary M. Musonda

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) coinfection has emerged as an important cause of morbidity and mortality. We determined the response to Truvada-based first-line combination antiretroviral therapy (cART) in HIV/HBV-coinfected verus HIV-monoinfected patients in Botswana. Methods. Hepatitis B virus surface antigen (HBsAg), HBV e antigen (HBeAg), and HBV deoxyribonucleic acid (DNA) load were determined from baseline and follow-up visits in a longitudinal cART cohort of Truvada-based regimen.We assessed predictors of HBV serostatus and viral suppression (undetectable HBV DNA) using logistic regression techniques. Results. Of 300 participants, 28 were HBsAg positive, giving an HIV/HBV prevalence of 9.3% (95% confidence interval [CI], 6.3-13.2), and 5 of these, 17.9% (95% CI, 6.1-36.9), were HBeAg positive. There was a reduced CD4+ T-cell gain in HIV/HBVcoinfected compared with HIV-monoinfected patients. Hepatitis B virus surface antigen and HBeAg loss was 38% and 60%, respectively, at 24 months post-cART initiation. The HBV DNA suppression rates increased with time on cART from 54% to 75% in 6 and 24 months, respectively. Conclusions. Human immunodeficiency virus/HBV coinfection negatively affected immunologic recovery compared with HIV-1C monoinfection. Hepatitis B virus screening before cART initiation could help improve HBV/HIV treatment outcomes and help determine treatment options when there is a need to switch regimens.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalOpen Forum Infectious Diseases
Volume3
Issue number3
DOIs
StatePublished - 2016
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Clinical Neurology

Keywords

  • Botswana
  • HIV/HBV coinfection
  • Hepatitis B virus
  • Tenofovir
  • Truvada

Fingerprint Dive into the research topics of 'Slow CD4<sup>+</sup> T-Cell recovery in human immunodeficiency virus/hepatitis B virus-coinfected patients initiating truvada-based combination antiretroviral therapy in Botswana'. Together they form a unique fingerprint.

Cite this